Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. (GH) filed a Form 144 notice for a planned sale of restricted stock that recently vested. The filing discloses that 3,213 shares of GH common stock are expected to be sold through broker Charles Schwab & Co., Inc. on or about 18 June 2025. The estimated aggregate market value of the proposed sale is $158,947. Compared with the company’s 123,888,045 shares outstanding, the transaction represents roughly 0.0026 % of total shares, indicating a de-minimis impact on the public float.
The seller—identified in the filing as Musa Tariq—acquired the shares on 15 June 2025 via the lapse of restrictions on equity compensation. Over the past three months Mr. Tariq has sold an additional 348 shares of Guardant Health stock across three transactions, generating $14,910 in gross proceeds. No relationship to the issuer is specified in the document, and the form states that the filer is unaware of any non-public material adverse information.
Because Form 144 covers proposed sales under Rule 144 and does not obligate the insider to complete the trade, investors typically view such filings as information events rather than firm commitments. Given the small size of the sale relative to Guardant Health’s market capitalization, the filing is unlikely to exert material pressure on share price but does provide incremental insight into insider trading intentions.